Detail akcie Skye Bioscience Rg online

Business Summary: Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Skye Bioscience Inc revenues was not reported. Net loss increased from $16.8M to $41.5M. Higher net loss reflects Research and development - Balancing increase from $9.9M to $29.3M (expense), Change in estimate for legal contingency decrease from $4.6M (income) to $0K, Gains from asset sales decrease of 85% to $181K (income).